The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series A | Alive

Total Raised


Last Raised

$14.19M | 2 yrs ago

About AcornMed

AcornMed, one of the brands under Xiangxin Biotechnology, specializes in solid tumor genetic testing and blood tumor genetic testing. The other brand, Xiangxin Technology, focuses on the development, production, and sales of in vitro diagnostic reagents.

AcornMed Headquarter Location

Room 5036, 5th Floor, 19 Haidian South Road

Beijing, Beijing,


+86 010-53606156

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AcornMed

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AcornMed is included in 6 Expert Collections, including Digital Health.


Digital Health

13,260 items


Medical Devices

7,911 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance



1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Health IT

7,900 items

Latest AcornMed News

AcornMed Selects Twist Bioscience Technology to Power Next Generation Precision Medicine Tests

Apr 8, 2021

Intellasia East Asia News 08-Apr-2021 Intellasia | BusinessWire | 9:00 AM SOUTH SAN FRANCISCO, Calif & BEIJING--(BUSINESS WIRE)--AcornMed Biotechnology Co., Ltd. (AcornMed), a precision medicine organization that specializes in the testing and analysis of solid and blood tumors, announced today that they will incorporate Twist Bioscience next generation sequencing (NGS) target enrichment and library preparation panels into AcornMed’s portfolio of tests designed to provide insight into the genetic predisposition and treatment regimens for patients, providing a more targeted therapeutic approach. “The partnership between Twist and AcornMed provides us with access to the global leader in high quality DNA synthesis at scale and quality. Twist understands the importance of panel performance and consistency when using genetic analysis to inform clinical treatment,” said Dr. Feng Lou, CTO and co-founder of AcornMed. “As NGS testing becomes a more mainstream, and widely adopted technology to enable precision medicine, we believe AcornMed’s products will be widely embraced to positively transform patient treatment and drive down the associated costs of health economics in China.” “Twist Bioscience’s proprietary DNA manufacturing process and quality control will play an increasingly important role in the development of in vitro diagnostic (IVD) panels, aiding in the adoption of NGS as a precision medicine tool. This is one of the reasons AcornMed selected Twist,” continued Dr. Lou. “As AcornMed begins to move testing into the IVD field, we can feel confident that the results will meet and exceed the NMPA’s expectations for patient assessment and diagnosis.” “We are pleased to enable AcornMed, an innovative and patient focused company, to accelerate their mission of providing exceptional precision medicine solutions for cancer identification and treatment,” said Emily Leproust, CEO and co-founder of Twist Bioscience. “The ability to stratify patients to assist in treatment based on their cancers’ genetic makeup represents a critical factor for the future of medicine.” About AcornMed AcornMed Biotechnology Co., Ltd. (AcornMed) is an innovation-driven National High-Tech Enterprise in China. With the head office located in Beijing Economic-Technological Development Area, AcornMed has established two R&D centers in Beijing and Tianjin, with a total area of 5,000 square Meters. Based on the self-developed big data platform for genomic analysis, AcornMed provides comprehensive solution of cancer precision medicine with genomics technologies. As a leading next generation sequencing (NGS) corporation in solid tumors and hematological malignancies, AcornMed has built a solid brand reputation in lung cancer, gastrointestinal tumors, urologic cancer, leukemia, and lymphoma. Over 30 clinical testing products have been launched and the application scenarios cover early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. Until now the company has served more than 500 hospitals and received commendations from many oncologists and laboratory experts. About Twist Bioscience Corporation Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

AcornMed Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AcornMed Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.